Bextra was developed in 2001 by Pfizer as one of a new class of painkillers. Bextra is a member of a class of prescription drugs called COX-2 selective nonsteroidal anti-inflammatory drugs, or NSAIDs. Bextra was approved by the FDA on November 16, 2001 for symptoms of osteoarthritis and rheumatoid arthritis, and to relieve painful menstrual cramps.

   On April 7, 2005, the FDA asked Pfizer to suspend sales of Bextra in the United States and Europe due to safety concerns of an increased risk of cardiovascular events (including heart attack and stroke) in patients on Bextra. 

   If you, or someone you know, has suffered an adverse cardiovascular event such as a heart attack or stroke taking Bextra, or if you are an attorney seeking specialized assistance, contact us by clicking here or by calling 419-841-9623. 

Related Links

• Bextra/Celebrex MDL Transfer Order 

• Bextra/Celebrex MDL Website 

• FDA COX-2 Selective (includes Bextra, Celebrex, and Vioxx) and Non-Selective Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) Information